1. Psoriatic Arthritis

2. Introduction to PsA

3. Key Cell Types and Activated Pathways in Psoriatic Arthritis

4. Role of IL-17 Signaling

5. Pharmacologic Agents Indicated for the Treatment of PsA

6. FUTURE 1 Efficacy and Safety of Secukinumab

7. FUTURE 2 Efficacy and Safety of SC Secukinumab

8. FUTURE 2: Efficacy of Secukinumab in Anti-TNF-Naive and Anti-TNF-IR Patients

9. FUTURE 5 Improvement in Radiographic Progression

10. Summary of Pooled Safety Across FUTURE 1 and FUTURE 2 Studies

11. Ixekizumab for the Treatment of PsA SPIRIT-P1 Results

12. SPIRIT-P2 Ixekizumab for the Treatment of PsA in TNF-IR Patients

13. Frequency of AEs Across SPIRIT-P1 and SPIRIT-P2 Studies

14. SPIRIT-H2H: Study Comparing Safety and Efficacy of Ixekizumab and Adalimumab in PsA

15. SPIRIT-H2H Results Primary and Secondary Outcomes at Week 24

16. Safety and Efficacy of Bimekizumab in Patients With PsA

17. GRAPPA Treatment Scheme

18. Enthesitis in PsA

19. IL-17 Inhibitors in the Treatment of Enthesitis

20. Dactylitis in PsA

21. IL-17 Inhibitors in the Treatment of Dactylitis

22. MAXIMISE Trial Managing Axial Manifestations in Patients with PsA

23. Concluding Remarks

25. Abbreviations

26. Abbreviations (cont)

27. Abbreviations (cont)